Psyrx Bio-Tech(IL:PSRX)
ILAÂ 62.40+0.10 (+0.16%)
IL:PSRX
Psyrx Bio-Tech financials statements
ILAÂ 62.40
At close:+0.10 (+0.16%)
Psyrx Bio-Tech (PSRX) Ratios
0 Followers
Psyrx Bio-Tech Ratios
IL:PSRX's free cash flow for Q2 2026 was $-473.07K. For the 2026 fiscal year, IL:PSRX's free cash flow was increased by $0.00 and operating cash flow was $-473.07K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.78 | 0.11 | 0.34 | 0.00 | 2.99 |
| Quick Ratio | 1.78 | 0.05 | 0.09 | 0.00 | 2.24 |
| Cash Ratio | 1.44 | 0.01 | 0.05 | 0.00 | 1.81 |
| Solvency Ratio | -9.04 | -1.24 | -1.53 | 0.00 | -4.53 |
| Operating Cash Flow Ratio | -0.42 | -0.88 | -0.86 | 0.00 | -3.28 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -5.35 | 0.00 | -57.61 |
| Net Current Asset Value | $ 258.60K | $ -1.50M | $ -6.42M | $ 0.00 | $ 8.23M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.37 | 0.00 | 0.10 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | -0.28 | 0.00 | 0.15 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | -0.40 | 0.00 | 0.13 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.27 | -0.11 | -0.78 | 0.00 | 1.54 |
| Debt Service Coverage Ratio | -238.40 | 0.00 | -9.56 | 0.00 | -48.87 |
| Interest Coverage Ratio | -238.90 | 0.00 | 0.00 | 0.00 | -96.02 |
| Debt to Market Cap | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.74 | 0.00 | 1.39 |
| Net Debt to EBITDA | 0.63 | 0.01 | -0.07 | 0.00 | 0.25 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 2898.29% | -103.12% | 0.00% | -532.68% |
| EBIT Margin | 0.00% | 7617.35% | -1321.99% | 0.00% | -19079.08% |
| EBITDA Margin | 0.00% | 6863.28% | -1214.93% | 0.00% | -18564.05% |
| Operating Profit Margin | 0.00% | 8080.43% | -1363.82% | 0.00% | -19079.08% |
| Pretax Profit Margin | 0.00% | 7617.35% | -1321.99% | 0.00% | -19277.78% |
| Net Profit Margin | 0.00% | 7617.35% | -1322.56% | 0.00% | -19301.96% |
| Continuous Operations Profit Margin | 0.00% | 7617.35% | -1322.56% | 0.00% | -19301.96% |
| Net Income Per EBT | 100.00% | 100.00% | 100.04% | 0.00% | 100.13% |
| EBT Per EBIT | 397.78% | 94.27% | 96.93% | 0.00% | 101.04% |
| Return on Assets (ROA) | -506.29% | -1220.06% | -380.59% | 0.00% | -163.83% |
| Return on Equity (ROE) | -1150.49% | 128.22% | 295.76% | 0.00% | -252.91% |
| Return on Capital Employed (ROCE) | -289.23% | 164.63% | 304.99% | 0.00% | -222.10% |
| Return on Invested Capital (ROIC) | -289.22% | 164.63% | 426.36% | 0.00% | -217.78% |
| Return on Tangible Assets | -506.29% | -1220.06% | -380.59% | 0.00% | -163.83% |
| Earnings Yield | -203.27% | -2711.68% | -15.78% | ― | -5.69% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | -0.64 | 10.98 | 0.00 | 0.08 |
| Payables Turnover | 0.02 | 3.51 | 1.39 | 0.00 | 0.32 |
| Inventory Turnover | 0.00 | 8.56 | 1.05 | 0.00 | 0.27 |
| Fixed Asset Turnover | 0.00 | 0.00 | 1.25 | 0.00 | 0.05 |
| Asset Turnover | 0.00 | -0.16 | 0.29 | 0.00 | 0.01 |
| Working Capital Turnover Ratio | 0.00 | 0.02 | -0.38 | 0.00 | 0.02 |
| Cash Conversion Cycle | -17959.67 | -630.22 | 118.44 | 0.00 | 4694.24 |
| Days of Sales Outstanding | 0.00 | -568.88 | 33.24 | 0.00 | 4484.97 |
| Days of Inventory Outstanding | 0.00 | 42.66 | 348.34 | 0.00 | 1365.73 |
| Days of Payables Outstanding | 17959.67 | 104.00 | 263.14 | 0.00 | 1156.46 |
| Operating Cycle | 0.00 | -526.22 | 381.58 | 0.00 | 5850.70 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.03 | -5.08 | -3.96 | 0.00 | -10.83 |
| Free Cash Flow Per Share | -0.03 | -5.08 | -3.96 | 0.00 | -11.99 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -1658.40 | 0.00 | -9.40 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -1658.40 | 0.00 | -9.40 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | -5.35 | 0.00 | -9.18 |
| Operating Cash Flow to Sales Ratio | 0.00 | 48.52 | -6.80 | 0.00 | -104.67 |
| Free Cash Flow Yield | -9.45% | -1727.40% | -8.12% | 0.00% | -3.42% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.49 | -0.04 | -6.34 | 0.00 | -17.56 |
| Price-to-Sales (P/S) Ratio | 0.00 | -2.81 | 83.83 | 0.00 | 3389.96 |
| Price-to-Book (P/B) Ratio | 5.66 | -0.05 | -18.75 | 0.00 | 44.42 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -10.58 | -0.06 | -12.32 | 0.00 | -29.27 |
| Price-to-Operating Cash Flow Ratio | -10.58 | -0.06 | -12.32 | 0.00 | -32.39 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | 0.00 | 0.00 | 0.00 | -0.15 |
| Enterprise Value Multiple | -1.33 | -0.03 | -6.97 | 0.00 | -18.01 |
| Enterprise Value | 993.26K | 63.34K | 103.25M | 0 | 511.56M |
| EV to EBITDA | -1.33 | -0.03 | -6.97 | 0.00 | -18.01 |
| EV to Sales | 0.00 | -2.08 | 84.70 | 0.00 | 3343.55 |
| EV to Free Cash Flow | -7.16 | -0.04 | -12.44 | 0.00 | -28.87 |
| EV to Operating Cash Flow | -7.16 | -0.04 | -12.45 | 0.00 | -31.94 |
| Tangible Book Value Per Share | 0.05 | -5.14 | -2.60 | 0.00 | 7.90 |
| Shareholders’ Equity Per Share | 0.05 | -6.22 | -2.60 | 0.00 | 7.90 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | -0.00 | 0.00 | -0.00 |
| Revenue Per Share | 0.00 | -0.10 | 0.58 | 0.00 | 0.10 |
| Net Income Per Share | -0.61 | -7.98 | -7.69 | 0.00 | -19.98 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 0.00 | 1.00 |
| Interest Burden | 3.98 | 1.00 | 1.00 | 0.00 | 1.01 |
| Research & Development to Revenue | 0.00 | -14.76 | 3.05 | 0.00 | 102.50 |
| SG&A to Revenue | 0.00 | -37.06 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.05 | 0.64 | 0.51 | 0.00 | 0.54 |
Currency in USD
